image credit- freepik
South Korea-based Hyundai Bioscience has announced that it can supply clinical trial doses of its broad-spectrum antiviral drug XAFTY® in response to growing global concern over infectious disease outbreaks caused by Ebola and hantavirus.
According to the company, niclosamide, the main ingredient of XAFTY®, has previously been reported to have inhibitory effects against Ebola and hantavirus.
The company stated, "In the ongoing Phase 2 clinical trial of XAFTY® for dengue fever in Vietnam, no adverse events have been reported so far," and claimed that "in a situation where two viruses are spreading simultaneously, XAFTY® could serve as an effective alternative."
Hyundai Bioscience added that, as a member of the Medical CBRN Defense Consortium (MCDC), a US Department of Defense-supported consortium, it will actively cooperate in responding to international public health crises.
